COSCIENS BIOPHARMA INC (CSCI) Stock Price, Forecast & Analysis
USA - NASDAQ:CSCI - CA22112H1010 - Common Stock
CSCI Key Statistics, Chart & Performance
The current stock price of CSCI is 2.72 USD. In the past month the price decreased by -31.14%. In the past year, price decreased by -32%.
CSCI Latest News, Press Relases and Analysis
CSCI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About CSCI
Company Profile
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Company Info
COSCIENS BIOPHARMA INC
C/O Norton Rose Fulbright Canada Llp, 222 Bay Street, Suite 3000, Po Box 53
TORONTO ONTARIO CA
Employees: 21
Phone: 18439003201
COSCIENS BIOPHARMA INC / CSCI FAQ
What does CSCI do?
COSCIENS Biopharma Inc. engages in the development and commercialization of diverse pharmaceutical and diagnostic products. The company is headquartered in Toronto, Ontario. The firm is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The firm's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
What is the stock price of COSCIENS BIOPHARMA INC today?
The current stock price of CSCI is 2.72 USD. The price decreased by -11.69% in the last trading session.
Does COSCIENS BIOPHARMA INC pay dividends?
CSCI does not pay a dividend.
What is the ChartMill technical and fundamental rating of CSCI stock?
CSCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for COSCIENS BIOPHARMA INC?
COSCIENS BIOPHARMA INC (CSCI) currently has 21 employees.
CSCI Technical Analysis
CSCI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CSCI. Both the profitability and financial health of CSCI have multiple concerns.
CSCI Financial Highlights
Over the last trailing twelve months CSCI reported a non-GAAP Earnings per Share(EPS) of -5.8. The EPS increased by 13.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.4% | ||
| ROE | -173.14% | ||
| Debt/Equity | 0.19 |